Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

详细信息    查看全文

• 作者：Noboru Yamamoto ; Koichi Goto ; Makoto Nishio…
• 关键词：Erlotinib ; EGFR mutations ; Non ; small ; cell lung cancer (NSCLC) ; First line ; Japanese patients ; Overall survival
• 刊名：International Journal of Clinical Oncology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：22
• 期：1
• 页码：70-78
• 全文大小：466KB
• 刊物类别：Medicine
• 刊物主题：Oncology; Surgical Oncology; Cancer Research;
• 出版者：Springer Japan
• ISSN：1437-7772
• 卷排序：22

文摘

BackgroundIn Japan, the clinical efficacy of erlotinib monotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was demonstrated in the phase II JO22903 trial, which reported a median progression-free survival of 11.8 months. Here we report final overall survival data from JO22903.